- Novartis to acquire ADC developer in a deal worth up to $1.5B<p>The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.</p>BioPharma Dive · 20d ago↗ source
- Cancer, immune drugmakers dominate VC funding so far in 2026<figure><div><img src="https://imgproxy.divecdn.com/nnTWCzHBd9_O2uNBVPF6xmxcO0M-nRFDpca5z-2Xchs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDMwNzQzODA0LmpwZ…BioPharma Dive · 20d ago↗ source
- Salk Institute’s president on NIH cuts, ‘all in’ on AI, and the Year of the BrainSAN DIEGO — From the president’s office at the Salk Institute, Gerald Joyce has a quintessential California view of hang gliders soaring over the Pacific Ocean. It’s been a little more turbulent…